2,732 results match your criteria Journal of Viral Hepatitis [Journal]


Low recurrence rate of hepatocellular carcinoma following ledipasvir and sofosbuvir treatment in a real-world chronic hepatitis C patients cohort.

J Viral Hepat 2019 Feb 11. Epub 2019 Feb 11.

Ramazan Idilman is a member of the Science Academy (BA).

The aims of the present study were to evaluate the efficacy and tolerability of ledipasvir/sofosbuvir (LDV/SOF) with or without ribavirin in the treatment of chronic hepatitis C (CHC) in patients with advanced liver disease and to analyze whether the use of LDV/SOF treatment is associated with a new occurrence of hepatocellular carcinoma (HCC) during and after LDV/SOF treatment. The Turkish Early Access Program provided LDV/SOF treatment to a total of 200 eligible CHC patients with advanced liver disease. The median follow-up period was 22 months. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13075DOI Listing
February 2019
1 Read

Chronic Hepatitis B: The interplay between intrahepatic lymphocyte population and viral antigens in relation to liver damage.

J Viral Hepat 2019 Feb 9. Epub 2019 Feb 9.

Instituto Multidisciplinario de Investigaciones en Patologías Pediátricas (IMIPP- CONICET-GCBA), Laboratorio de Biología Molecular, División Patología, Hospital de Niños Ricardo Gutiérrez, Gallo 1330, C1425EFD, Buenos Aires, Argentina.

In Chronic Hepatitis B (CHB) infection, virus and immune response interplay is thought to be responsible for pathogenesis. Yet, the impact of each immune cell population and viral protein expression in liver damage is still unknown. Our aim was to study the interplay between intrahepatic immune response and viral activity in relation to CHB liver damage. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13078DOI Listing
February 2019
2 Reads

Vitamin D deficiency and health-related quality of life in chronic hepatitis C.

J Viral Hepat 2019 Feb 9. Epub 2019 Feb 9.

Hepatology Unit, Department of Clinical Medicine, Sapienza University of Rome, Rome, Italy.

Vitamin D deficiency is common in patients with chronic liver disease, including chronic hepatitis C (CHC). However, the interplay between serum 25-hydroxy-vitamin-D (25-OH-D) and health-related-quality-of-life (HRQoL) in CHC subjects has never been investigated. The study aimed to analyze the relationship between vitamin D deficiency and HRQoL in CHC patients. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13076DOI Listing
February 2019
1 Read

Real-world safety and effectiveness of ombitasvir/paritaprevir/ritonavir ± dasabuvir ± ribavirin in hepatitis C virus genotype 1- and 4-infected patients with diverse comorbidities and comedications: A pooled analysis of post-marketing observational studies from 13 countries.

J Viral Hepat 2019 Feb 10. Epub 2019 Feb 10.

Department of Infectious Diseases and Hepatology, Medical University of Białystok, Białystok, Poland.

Ombitasvir/paritaprevir/ritonavir±dasabuvir±ribavirin (OBV/PTV/r±DSV±RBV) regimens show high efficacy and good tolerability in clinical trials for chronic hepatitis C virus (HCV) genotypes (GT) 1 or 4. To evaluate whether these results translate to clinical practice, data were pooled from observational studies across 13 countries. Treatment-naïve or -experienced patients, with or without cirrhosis, received OBV/PTV/r±DSV±RBV according to approved local labels and clinical practice. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13080DOI Listing
February 2019
1 Read

Efficacy and Safety of Ruzasvir 60 mg and Uprifosbuvir 450 mg for 12 Weeks in Adults With Chronic Hepatitis C Virus Genotype 1, 2, 3, 4, or 6 Infection.

J Viral Hepat 2019 Feb 9. Epub 2019 Feb 9.

Merck& Co., Inc, Kenilworth, NJ, USA.

In clinical trials, the three-drug regimen of ruzasvir (RZR) 60 mg, uprifosbuvir (UPR) 450 mg, and grazoprevir 100 mg, with or without ribavirin has demonstrated promising efficacy and excellent tolerability across a wide range of hepatitis C virus (HCV)-infected individuals. The present study assessed the efficacy and safety of the two-drug combination of RZR 60 mg plus UPR 450 mg administered for 12 weeks in participants with HCV genotype (GT) 1-6 infection. In this open-label clinical trial, treatment-naive or -experienced and cirrhotic or noncirrhotic participants with chronic HCV GT1-6 infection received RZR 60 mg plus UPR 450 mg orally once daily for 12 weeks (NCT02759315/protocol PN035). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13079
Publisher Site
http://dx.doi.org/10.1111/jvh.13079DOI Listing
February 2019
6 Reads

Age-stratified anti-HAV positivity in Pune, India after two decades: Has voluntary vaccination impacted overall exposure to HAV?

J Viral Hepat 2019 Feb 9. Epub 2019 Feb 9.

Department of Communicable Diseases, Interactive Research School for Health Affairs (IRSHA), Bharati Vidyapeeth (Deemed to be University), Pune, India.

The degree of transmission of hepatitis A virus (HAV) is inversely proportional to the socioeconomic status of a community. Serosurveys conducted at Pune, India during 1982-98 documented significant reduction in HAV exposure of pediatric, higher socioeconomic status (HSS) population. Anti-HAV positivity (ELISA) in age-stratified Pune population representing HSS and lower middle socioeconomic status (LMSS) (n=1065) and infants till the age of 15months (n=690) was determined in 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13074DOI Listing
February 2019
3 Reads

Diabetes poses a higher risk of hepatocellular carcinoma and mortality in patients with chronic hepatitis B: a population-based cohort study.

J Viral Hepat 2019 Feb 9. Epub 2019 Feb 9.

Community Medicine Research Center, Chang Gung Memorial Hospital, Keelung branch, Keelung, 204, Taiwan.

Diabetes mellitus may be a risk factor of HCC development in chronic hepatitis B infected patients and affect the all-cause mortality. This study aimed to examine whether DM was associated with the development of HCC with CHB and affected the all-cause mortality. A total of 2,966 CHB patients newly diagnosed with DM in 2000 were retrieved from the Longitudinal Cohort of Diabetes Patients database and used propensity scores matching based on age, sex-gender, alcohol-related liver disease, and baseline liver cirrhosis to compare with the non-DM patients from the Taiwanese National Health Insurance Research Database. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13077
Publisher Site
http://dx.doi.org/10.1111/jvh.13077DOI Listing
February 2019
2 Reads

High prevalence and poor linkage to care of transfusion transmitted infections among blood donors in Dar-es-Salaam, Tanzania.

J Viral Hepat 2019 Feb 3. Epub 2019 Feb 3.

Department of Hepatology, Imperial College London, St Mary's Hospital, London, UK.

Blood transfusion is one of the most commonly relied upon therapies in sub-Saharan Africa. Existing safeguards recommended include systematic screening for transfusion-transmitted infections and restricted voluntary non-remunerated blood donor selection. We report the transfusion-transmitted infection screening and notification practice at a large urban blood transfusion center in Dar-es-Salaam, Tanzania. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13073DOI Listing
February 2019
1 Read

MicroRNA-let-7c suppresses hepatitis C virus replication by targeting Bach1 for induction of heme oxygenase-1 expression.

J Viral Hepat 2019 Jan 31. Epub 2019 Jan 31.

Graduate Institute of Medicine, College of Medicine, Kaohsiung Medical University, Kaohsiung, Taiwan.

MicroRNAs (miRNAs) are small noncoding RNAs that are central factors between hepatitis C virus (HCV) and host cellular factors for viral replication and liver disease progression, including liver fibrosis, cirrhosis, and hepatocellular carcinoma. In the present study, we found that overexpressing miR-let-7c markedly reduced HCV replication because it induced heme oxygenase-1 (HO-1) expression by targeting HO-1 transcriptional repressor Bach1, ultimately leading to stimulating an antiviral interferon response and blockade of HCV viral protease activity. In contrast, the antiviral actions of miR-let-7c were attenuated by miR-let-7c inhibitor treatment, exogenously expressing Bach1 or suppressing HO-1 activity and expression. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13072DOI Listing
January 2019
1 Read

HBV T1719G mutation reduced HBV replication through mutant Enh II and HBx protein in vitro.

J Viral Hepat 2019 Jan 31. Epub 2019 Jan 31.

Department of Microbiology & Infectious Disease Center, School of Basic Medical Science, Peking University Health Science Center, 38 Xueyuan Road, Beijing, 100191, P.R. China.

It was repeatedly reported that the hepatitis B virus (HBV) T1719G mutation was very common and related to progression and malignancy of liver disease. However, its effect on viral replication efficiency remains unclear. In this study, we aimed to evaluate the function and mechanisms of the T1719G mutation on viral replicative capacity. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13070
Publisher Site
http://dx.doi.org/10.1111/jvh.13070DOI Listing
January 2019
3 Reads

Interferon-free Therapy as the Cause of White Matter Tracts and Cerebral Perfusion Recovery in Patients with Chronic Hepatitis C.

J Viral Hepat 2019 Jan 31. Epub 2019 Jan 31.

Department of General Radiology, Interventional Radiology and Neuroradiology, Chair of Radiology, Wroclaw Medical University, Borowska 213, 50-556, Wroclaw, Poland.

The purpose of this study was to assess cerebral microstructural and perfusion changes in patients with chronic hepatitis C virus (HCV) infection before and after interferon-free therapy, using advanced magnetic resonance (MR) techniques. Eleven HCV-positive patients underwent diffusion tensor imaging (DTI) and perfusion weighted imaging (PWI) using a 1.5T MR unit, before and 24 weeks after completion of interferon-free therapy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13069DOI Listing
January 2019

Immunological biomarkers as indicators for outcome after discontinuation of nucleos(t)ide analogue therapy in patients with HBeAg negative chronic hepatitis B.

J Viral Hepat 2019 Jan 31. Epub 2019 Jan 31.

Department of Clinical and Experimental Sciences, Faculty of Medicine, University of Southampton, United Kingdom.

The optimal duration of treatment with nucleos(t)ide analogues (NAs) for patients with HBeAg-negative Chronic Hepatitis B (CHB) is unknown. The aim of this study was to identify an immune signature associated with off-treatment remission to NA therapy. We performed microarray analysis of PBMCs from six patients with chronic hepatitis B who stopped NA therapy (3 with off-treatment remission, 3 with relapse) and 5 patients with chronic HBV infection (previously termed "inactive carriers") served as controls. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13068
Publisher Site
http://dx.doi.org/10.1111/jvh.13068DOI Listing
January 2019
4 Reads

Testing for hepatitis C virus infection in UK Prisons: what actually happens?

J Viral Hepat 2019 Jan 31. Epub 2019 Jan 31.

National Institute for Health Research Nottingham Biomedical Research Centre, Nottingham University Hospitals NHS Trust and the University of Nottingham, Nottingham, NG7 2UH, United Kingdom.

Prisons are a key demographic in the drive to eradicate hepatitis C virus (HCV) as a major public health threat. We have assessed the impact of the recently introduced national opt-out policy on the current status of HCV testing in 14 prisons in the East Midlands (UK). We analysed testing rates pre- and post-introduction of opt-out testing, together with face-to-face interviews with prison healthcare and management staff in each prison. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13071DOI Listing
January 2019

Monitoring the hepatitis C epidemic in England and evaluating intervention scale-up using routinely collected data.

J Viral Hepat 2019 Jan 21. Epub 2019 Jan 21.

Statistics Modelling and Economics Department, National Infections Service Public Health England, London, UK.

In England, 160,000 individuals were estimated to be chronically infected with hepatitis C virus (HCV) in 2005 and the burden of severe HCV-related liver disease has increased steadily for the past 15 years. Direct-acting antiviral treatments can clear infection in most patients, motivating HCV elimination targets. However, the current burden of HCV is unknown and new methods are required to monitor progress. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13063
Publisher Site
http://dx.doi.org/10.1111/jvh.13063DOI Listing
January 2019
3 Reads

Sofosbuvir/Velpatasvir/Voxilaprevir for Patients with HCV Who Previously Received a Sofosbuvir/Velpatasvir-Containing Regimen: Results from a Retreatment Study.

J Viral Hepat 2019 Jan 21. Epub 2019 Jan 21.

University of Alberta, Edmonton, AB, Canada.

This study evaluated 12-week retreatment with sofosbuvir/velpatasvir/voxilaprevir in patients with chronic hepatitis C virus (HCV) infection who did not achieve sustained virologic response after previous treatment with a sofosbuvir and velpatasvir-containing regimen. All 31 patients maintained a sustained virologic response 12 weeks after the last sofosbuvir/velpatasvir/voxilaprevir dose. This article is protected by copyright. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13067
Publisher Site
http://dx.doi.org/10.1111/jvh.13067DOI Listing
January 2019
3 Reads

Hepatitis D virus infection, cirrhosis, and hepatocellular carcinoma in The Gambia.

J Viral Hepat 2019 Jan 20. Epub 2019 Jan 20.

Division of Cancer Epidemiology and Genetics, National Cancer Institute, Rockville, Maryland, USA.

Hepatocellular carcinoma (HCC) incidence is high in The Gambia and hepatitis B virus (HBV) infection is the main cause. People co-infected with HBV and hepatitis D virus (HDV) have an even greater risk of HCC and cirrhosis. Using a new HDV quantitative microarray antibody capture (Q-MAC) assay, we evaluated the association between HDV infection and HCC or cirrhosis among participants in The Gambia Liver Cancer Study. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13065
Publisher Site
http://dx.doi.org/10.1111/jvh.13065DOI Listing
January 2019
4 Reads

Hepatitis e virus in spanish donors and the necessity for screening.

J Viral Hepat 2019 Jan 19. Epub 2019 Jan 19.

Infectious Diseases Unit. Instituto Maimonides de Investigación Biomédica de Córdoba (IMIBIC). Hospital Universitario Reina Sofía de Córdoba, Universidad de Córdoba. Cordoba, Spain.

Hepatitis E virus (HEV) represents a major health problem worldwide. As the course of HEV cases is often subclinical, asymptomatic infections could represent an important source of viral spread and infection via routes such as blood donations. Before universal screening for HEV in blood donations can be implemented, studies evaluating the incidence of infection are needed to establish the potential risk of viral transmission. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13064DOI Listing
January 2019
3 Reads

Clinical features and determinants of chronicity in hepatitis E virus infection.

J Viral Hepat 2019 Jan 12. Epub 2019 Jan 12.

Division of Clinical Care and Research, Institute of Human Virology, University of Maryland, Baltimore, Maryland.

Hepatitis E virus (HEV) has traditionally been associated with an acute, self-limiting hepatitis and is not known to have any chronic sequelae. HEV genotypes 1 and 2, which are human pathogens, have been associated with this self-limiting presentation, in both sporadic and epidemic settings. HEV genotype 3, which is zoonotically transmitted, is increasingly being reported as a cause of chronic infection in immunocompromised patients. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13059
Publisher Site
http://dx.doi.org/10.1111/jvh.13059DOI Listing
January 2019
5 Reads

Serum HBcrAg is better than HBV RNA and HBsAg in reflecting intrahepatic covalently closed circular DNA.

J Viral Hepat 2019 Jan 10. Epub 2019 Jan 10.

Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China.

The correlation between serum HBcrAg and HBV RNA is unclear, and correlations of intrahepatic cccDNA with HBcrAg, HBV RNA and HBsAg are rarely reported in the same cohort. This study aimed to assess the correlation of HBcrAg with HBV RNA and HBsAg, and investigate whether serum HBcrAg is superior to serum HBV RNA and HBsAg in reflecting intrahepatic HBV cccDNA in HBeAg-positive and HBeAg-negative CHB patients. In this study, 85 HBeAg-positive and 25 HBeAg-negative patients who have never received antiviral therapy were included. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13061
Publisher Site
http://dx.doi.org/10.1111/jvh.13061DOI Listing
January 2019
9 Reads

HCV genotype 6 prevalence, spontaneous clearance and diversity among elderly members of the Li ethnic minority in Baisha County, China.

J Viral Hepat 2019 Jan 10. Epub 2019 Jan 10.

Institute of Clinical Blood Transfusion, Guangzhou Blood Center, Guangzhou, Guangdong, China.

The epidemiology of hepatitis C virus varies widely across geographical regions and ethnic groups. Our previous study showed that 6 strains isolated from Baisha County, Hainan Island, China, were all new genotype 6 (gt6) subtypes which differed significantly from subtypes of other regions. In the current study, we conducted a comprehensive epidemiological survey of HCV in the Li ethnic group, native to Baisha County. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13062
Publisher Site
http://dx.doi.org/10.1111/jvh.13062DOI Listing
January 2019
5 Reads

Awareness of Chronic Viral Hepatitis in the United States: An Update from National Health and Nutrition Examination Survey.

J Viral Hepat 2019 Jan 10. Epub 2019 Jan 10.

Section of Gastroenterology and Hepatology, Baylor College of Medicine, Houston, TX, U.S.

The World Health Organization has set the goal of reducing the hepatitis-related mortality rate by 65% between 2015 and 2030. Diagnosis and awareness of infection is the first essential step towards achieving this goal. Our study examined the current awareness rate of chronic viral hepatitis in the U. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13060
Publisher Site
http://dx.doi.org/10.1111/jvh.13060DOI Listing
January 2019
4 Reads

Early steep decline of liver stiffness predicts histological reversal of fibrosis in chronic hepatitis B patients treated with entecavir.

J Viral Hepat 2019 Jan 9. Epub 2019 Jan 9.

Liver Research Center, Beijing Friendship Hospital, Capital Medical University, Beijing Key Laboratory of Translational Medicine on Liver Cirrhosis, National Clinical Research Center for Digestive Disease, Beijing, China.

It is unknown whether dynamic changes of liver stiffness measurement (LSM) can predict the reversibility of fibrosis. Therefore, we evaluated the utility of LSM changes in predicting histological changes of fibrosis in patients with chronic hepatitis B (CHB) on antiviral therapy. In a prospective cohort of CHB patients treated with entecavir, virological and biochemical measurement along with LSM were measured at baseline and every 6 months. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13058
Publisher Site
http://dx.doi.org/10.1111/jvh.13058DOI Listing
January 2019
6 Reads

Soluble programmed death-1 is a useful indicator for inflammatory and fibrosis severity in chronic hepatitis B.

J Viral Hepat 2018 Dec 22. Epub 2018 Dec 22.

Department of Infectious Disease, the Third Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.

Elevated programmed death-1 (PD-1) has been found in immune cells in viral infections and plays an important role in infection persistence. The soluble form of PD-1 (sPD-1) is involved in tumours and viral infections. The aim of this study was to investigate the role of sPD-1 in chronic hepatitis B (CHB). Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13055DOI Listing
December 2018

Genomic variability of within-host hepatitis C variants in acute infection.

J Viral Hepat 2018 Dec 22. Epub 2018 Dec 22.

School of Medical Sciences, UNSW, Sydney, New South Wales, Australia.

Interactions between the host immune system and the viral variants determine persistence of hepatitis C virus (HCV) infection after the acute phase of infection. This study describes the genetic variability of within-host HCV viral variants in acute infection and correlates it with host- and virus-related traits and infection outcome. Next generation sequence data (Illumina, MiSeq platform) of viral genomes from 116 incident acute infections (within 180 days of infection) were analysed to determine all the single nucleotide polymorphism (SNP) frequencies above a threshold of 0. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13051
Publisher Site
http://dx.doi.org/10.1111/jvh.13051DOI Listing
December 2018
4 Reads

Improvement of bone mineral density and markers of proximal renal tubular function in chronic hepatitis B patients switched from tenofovir disoproxil fumarate to tenofovir alafenamide.

J Viral Hepat 2018 Dec 21. Epub 2018 Dec 21.

Asian Pacific Liver Center at Saint Vincent Medical Center, University of Southern California, Los Angeles, California.

Tenofovir alafenamide (TAF) is a novel prodrug that reduces tenofovir plasma levels by 90% compared to tenofovir disoproxil fumarate (TDF), resulting in decreased bone mineral density (BMD) loss and renal toxicity. We aimed to study changes in BMD and markers of renal function of chronic hepatitis B (CHB) patients previously treated with TDF who were switched to TAF in as early as 12 weeks. This was a prospective single-arm open-label study of 75 CHB patients treated with TDF 300 mg daily who were switched to TAF 25 mg daily and followed for 24 weeks. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13053DOI Listing
December 2018

Molecular epidemiology of hepatitis B virus mutants associated with vaccine escape, drug resistance and diagnosis failure.

J Viral Hepat 2018 Dec 21. Epub 2018 Dec 21.

Facultad de Farmacia y Bioquímica, Cátedra de Virología, Universidad de Buenos Aires, Buenos Aires, Argentina.

The massive implementation of the vaccine and antiviral agents against hepatitis B virus (HBV), targeting the envelope and viral polymerase genes, induces a selection pressure that might lead to the emergence of variants that impair the effectiveness of the vaccine, diagnostic methods and antiviral therapy. The aim of this study was to evaluate the prevalence of HBV vaccine escape mutants (VEMs), diagnostic failure mutants (DFMs) and treatment resistance mutants (ARMs) among individuals from Buenos Aires, Argentina. HBV surface antigen and polymerase sequences obtained from serum samples of 530 HBV-infected individuals were analysed. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13052DOI Listing
December 2018
1 Read
3.909 Impact Factor

Serum hepatitis B core-related antigen is an effective tool to categorize patients with HBeAg-negative chronic hepatitis B.

J Viral Hepat 2018 Dec 21. Epub 2018 Dec 21.

Dipartimento di Scienze Mediche e Chirurgiche, Centro di Ricerca per lo Studio delle Epatiti, Università degli Studi di Bologna, Bologna, Italy.

The discrimination between active chronic hepatitis B (CHB) and the clinically quiescent infection (CIB) is not always easy, as a significant portion of patients falls in a "grey" zone. Hepatitis B core-related antigen (HBcrAg) is a now quantifiable serological marker with potential applications in diagnosis and therapy monitoring. The aim of the present study was to evaluate the HBcrAg serum levels in HBeAg-negative HBV infection, and its ability in identifying the clinical profile, in comparison with HBsAg serum levels. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13054DOI Listing
December 2018

Hepatitis C virus infection in Australian psychiatric inpatients: A multicenter study of seroprevalence, risk factors and treatment experience.

J Viral Hepat 2018 Dec 21. Epub 2018 Dec 21.

Hepatology and Liver Transplantation Unit, Flinders Medical Centre, Adelaide, South Australia, Australia.

Screening and treatment for hepatitis C virus (HCV) infection were not prioritised in psychiatric patients due to adverse neuropsychiatric effects of interferon therapy despite reports of high prevalence. However, with the safe new antiviral drugs, HCV eradication has become a reality in these patients. The aim of this study was to report HCV seroprevalence, risk factors and treatment model in an Australian cohort. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13056
Publisher Site
http://dx.doi.org/10.1111/jvh.13056DOI Listing
December 2018
2 Reads

Incidence of hepatitis E virus infection among blood donors in a high endemic area of Central Italy.

J Viral Hepat 2018 Dec 7. Epub 2018 Dec 7.

Department of Infectious Diseases, National Institute of Health, Rome, Italy.

In Europe, autochthonous hepatitis E virus (HEV) infection is mainly a foodborne zoonosis, but it is also transmitted by blood transfusion. Despite the numerous prevalence surveys, only a few studies have investigated HEV incidence. We aimed to determine HEV incidence and risk factors among blood donors in a hyperendemic area in Central Italy. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13049DOI Listing
December 2018
2 Reads

Role of soluble inflammatory mediators and different immune cell populations in early control of symptomatic acute hepatitis C virus infection.

J Viral Hepat 2018 Dec 8. Epub 2018 Dec 8.

Department of Gastroenterology, Hepatology and Endocrinology, Hannover Medical School, Hannover, Germany.

The natural course of acute Hepatitis C Virus (aHCV) infection is highly heterogeneous, and only few biomarkers have been identified to reliably predict the outcome of infection. We analysed a large panel of soluble inflammatory mediators, immune cell frequencies and phenotypes using peripheral blood samples from 26 patients with symptomatic aHCV infection from a controlled randomized clinical trial (ISRCTN88729946, www.isrctn. Read More

View Article

Download full-text PDF

Source
https://onlinelibrary.wiley.com/doi/abs/10.1111/jvh.13050
Publisher Site
http://dx.doi.org/10.1111/jvh.13050DOI Listing
December 2018
1 Read

Influence of miR-520e-mediated MAPK signaling pathway on HBV replication and regulation of hepatocellular carcinoma cells via targeting EphA2.

J Viral Hepat 2018 Dec 6. Epub 2018 Dec 6.

Department of Health Examination, Qilu Hospital, Shandong University, Jinan, 250012, China.

We determined the role of miR-520e in the replication of hepatitis B virus (HBV) and the growth of hepatocellular carcinoma (HCC) cells. MiR-520e and EPH receptor A2 (EphA2) in HBV-positive HCC tissues and cells were detected and we studied the impact of miR-520e and the EphA2 receptor in cellular and murine HBV replication models. We find that MiR-520e was up-regulated and EphA2 was down-regulated in HBV-positive HCC tissues and cells. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13048DOI Listing
December 2018
4 Reads

Clinical effectiveness, cost effectiveness and acceptability of community-based treatment of hepatitis C virus infection: A mixed method systematic review.

J Viral Hepat 2018 Dec 5. Epub 2018 Dec 5.

School of Public Health and Social Work, Faculty of Health, Institute of Health and Biomedical Innovation (IHBI), Queensland University of Technology, Brisbane, Queensland, Australia.

Several community-based models for treating hepatitis C virus (HCV) infection have been implemented to improve treatment accessibility and health outcomes. However, there is a lack of knowledge regarding how well these models achieve the desired goals. We conducted a mixed-method systematic review of quantitative and qualitative evidence about clinical effectiveness, cost effectiveness and acceptability of community-based HCV treatment models. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13045DOI Listing
December 2018
3 Reads

Hepatitis C virus genotype 3 was associated with the development of hepatocellular carcinoma in Korea.

J Viral Hepat 2018 Dec 5. Epub 2018 Dec 5.

Department of Internal Medicine, Gyeongsang National University School of Medicine and Gyeongsang National University Hospital, Jinju, Korea.

Although hepatitis C virus (HCV) genotype 3 infection is thought to be an important risk factor for hepatocellular carcinoma (HCC), current evidence is limited because only a few Western studies have evaluated the occurrence of HCC in patients with HCV genotype 3 infection. We evaluated the impact of genotype 3 and non-3 on HCC incidence and on disease progression in chronic HCV patients; this is the first study reporting such findings in an Asian population. We performed a retrospective cohort study using the data of 1448 consecutive chronic HCV patients evaluated at three centres in Korea between January 2005 and December 2016. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13047DOI Listing
December 2018
2 Reads

Durable control of hepatitis C through interferon-free antiviral combination therapy immediately prior to allogeneic haematopoietic stem cell transplantation.

J Viral Hepat 2018 Dec 5. Epub 2018 Dec 5.

Department of Pediatric Hematology/Oncology, University Children's Hospital Münster, Münster, Germany.

Chronic hepatitis C virus (HCV) infection carries increased risks for morbidity and mortality in patients undergoing allogeneic haematopoietic stem cell transplantation (HSCT) but has become curable through the advent of directly acting antiviral compounds. Current guidelines of the American Society for Blood and Marrow Transplantation (ASBMT) recommend that HCV-infected HSCT candidates preferably start and complete therapy prior to transplant. However, this is often not feasible due to time constraints or treatment-limiting comorbidities, conditions and treatments. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13046DOI Listing
December 2018
3 Reads

Dynamic changes in innate immune responses during direct-acting antiviral therapy for HCV infection.

J Viral Hepat 2018 Nov 19. Epub 2018 Nov 19.

Liver Center and Gastrointestinal Division, Department of Medicine, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts.

The role of the endogenous interferon (IFN) system has been well characterized during IFN-based therapy for chronic hepatitis C virus (HCV) infection; less is known for direct-acting antivirals (DAAs). In this phase 3b open-label study, we assessed changes in IFN-stimulated genes (ISGs) in non-cirrhotic treatment-naïve or pegIFN/RBV-experienced HCV-GT1a-infected patients receiving paritaprevir/ritonavir/ombitasvir + dasabuvir + ribavirin (PrOD + R) for 12 weeks. ISG expression was quantified from peripheral blood mononuclear cells at baseline, treatment weeks (TW)2, TW4, TW8, end of treatment (EOT) and at post-treatment week 12. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13041
Publisher Site
http://dx.doi.org/10.1111/jvh.13041DOI Listing
November 2018
16 Reads

Variants of hepatitis B virus surface antigen observed during therapy with nucleic acid polymer REP 2139-Ca have no influence on treatment outcome and its detection by diagnostic assays.

J Viral Hepat 2018 Nov 19. Epub 2018 Nov 19.

Institute of Virology, Technische Universität München, Munich, Germany.

The treatment of patients suffering from HBeAg-positive chronic hepatitis B with REP 2139-Ca resulted in potent reductions in HBsAg and HBV DNA, seroconversion to anti-HBs and the establishment of functional control of infection. In this cohort of 12 patients, we investigated whether differences between HBsAg sequences might explain the lack of response to REP 2139-Ca observed in 3 of 12 patients. We also assessed if the reduction or complete loss of HBsAg in serum observed during therapy were caused by mutations in the "a" determinant preventing the detection of HBsAg by standard diagnostic assays. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13044
Publisher Site
http://dx.doi.org/10.1111/jvh.13044DOI Listing
November 2018
8 Reads

Applying core theory and spatial analysis to identify hepatitis C virus infection "core areas" in British Columbia, Canada.

J Viral Hepat 2018 Nov 17. Epub 2018 Nov 17.

School of Population and Public Health, University of British Columbia, Vancouver, British Columbia, Canada.

"Core areas" of transmission for bacterial sexually transmitted infections have been identified. However, it is unclear whether core areas apply to viral infections, such as hepatitis C virus (HCV). We used geographic mapping and spatial analysis to identify distinct core areas of HCV infection in British Columbia (BC) using the BC Hepatitis Testers Cohort (BC-HTC), 1990-2013. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13043DOI Listing
November 2018
6 Reads

High response and re-infection rates among people who inject drugs treated for hepatitis C in a community needle and syringe programme.

J Viral Hepat 2018 Nov 13. Epub 2018 Nov 13.

Department of Molecular and Clinical Medicine, University of Dundee, Dundee, UK.

To achieve WHO hepatitis C virus (HCV) elimination targets by 2030, mathematical models suggest there needs to be significant scale-up of treatment among people who inject drugs (PWID). We tested whether people who actively inject drugs can be recruited and treated successfully through a community needle and syringe programme (NSP), and assessed rates of re-infection. 105 HCV RNA positive participants were enrolled prospectively. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13035
Publisher Site
http://dx.doi.org/10.1111/jvh.13035DOI Listing
November 2018
9 Reads

Glecaprevir/Pibrentasvir in patients with chronic HCV genotype 3 infection: An integrated phase 2/3 analysis.

J Viral Hepat 2018 Nov 12. Epub 2018 Nov 12.

Denver Health Medical Center, Denver, Colorado.

Glecaprevir coformulated with pibrentasvir (G/P) is approved to treat hepatitis C virus (HCV) infection and was highly efficacious in phase 2 and 3 studies. Treating HCV genotype (GT) 3 infection remains a priority, as these patients are harder to cure and at a greater risk for liver steatosis, fibrosis progression and hepatocellular carcinoma. Data were pooled from five phase 2 or 3 trials that evaluated 8-, 12- and 16-week G/P in patients with chronic HCV GT3 infection. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13038
Publisher Site
http://dx.doi.org/10.1111/jvh.13038DOI Listing
November 2018
8 Reads

Efficacy and safety of antiviral treatment on blocking the mother-to-child transmission of hepatitis B virus: A meta-analysis.

J Viral Hepat 2018 Nov 11. Epub 2018 Nov 11.

Department of Epidemiology, Second Military Medical University, Shanghai, China.

Nucleo(t)side analogues (NAs) have been administered as adjunctive therapy to interrupt the mother-to-child transmission (MTCT) of hepatitis B virus (HBV). The efficacy and safety of this method remain controversial. A meta-analysis was conducted to evaluate the efficacy and safety of NAs treatment during pregnancy. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13036
Publisher Site
http://dx.doi.org/10.1111/jvh.13036DOI Listing
November 2018
9 Reads

The impact of currently licensed therapies on viral and immune responses in chronic hepatitis B: Considerations for future novel therapeutics.

J Viral Hepat 2019 Jan 11;26(1):4-15. Epub 2018 Dec 11.

Barts Liver Centre, Blizard Institute, Barts and The London School of Medicine & Dentistry, Queen Mary University of London, London, UK.

Despite the availability of a preventative vaccine, chronic hepatitis B (CHB) remains a global healthcare challenge with the risk of disease progression due to cirrhosis and hepatocellular carcinoma. Although current treatment strategies, interferon and nucleos(t)ide analogues have contributed to reducing morbidity and mortality related to CHB, these therapies are limited in providing functional cure. The treatment paradigm in CHB is rapidly evolving with a number of new agents in the developmental pipeline. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13040
Publisher Site
http://dx.doi.org/10.1111/jvh.13040DOI Listing
January 2019
11 Reads

The accuracy of baseline viral load for predicting the efficacy of elbasvir/grazoprevir in participants with hepatitis C virus genotype 1a infection: An integrated analysis.

J Viral Hepat 2018 Nov 9. Epub 2018 Nov 9.

Merck & Co., Inc., Kenilworth, New Jersey.

European treatment guidelines for hepatitis C virus (HCV) infection recommend that people with genotype (GT) 1a infection and baseline viral load ≤800 000 IU/mL receive elbasvir/grazoprevir (EBR/GZR) for 12 weeks, and those with baseline viral load >800 000 IU/mL receive EBR/GZR plus ribavirin for 16 weeks. This analysis was conducted to clarify whether baseline viral load can serve as an accurate, sensitive or specific stratification factor for defining EBR/GZR regimens. In this post hoc, integrated analysis, participants with GT1a infection who received EBR 50 mg/GZR 100 mg for 12 weeks were stratified according to baseline viral load. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13037
Publisher Site
http://dx.doi.org/10.1111/jvh.13037DOI Listing
November 2018
11 Reads

Improved liver transplant waitlist mortality and lower risk of disease progression among chronic hepatitis C patients awaiting liver transplantation after the introduction of direct-acting antiviral therapies in the United States.

J Viral Hepat 2018 Nov 9. Epub 2018 Nov 9.

Division of Gastroenterology and Hepatology, Alameda Health System - Highland Hospital, Oakland, California.

Direct-acting antiviral (DAA) therapies for chronic hepatitis C virus (HCV) infection achieve high cure rates, reducing HCV-related disease progression to cirrhosis and hepatocellular carcinoma. We aim to evaluate the impact of DAAs on US liver transplant (LT) waitlist outcomes. We retrospectively evaluated US adults (age ≥18) with and without chronic HCV listed for LT before and after the widespread use of sofosbuvir, allowing a 6-month period after approval (Era 1: 1/1/2002-5/31/2014 vs Era 2: 6/1/2014-12/31/2016) using the United Network for Organ Sharing registry. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13039
Publisher Site
http://dx.doi.org/10.1111/jvh.13039DOI Listing
November 2018
9 Reads
3.910 Impact Factor

The comprehensive outcomes of hepatitis C virus infection: A multi-faceted chronic disease.

J Viral Hepat 2018 Nov;25 Suppl 3:6-14

Department of Hygiene, Epidemiology and Medical Statistics, Medical School of National and Kapodistrian University of Athens, Athens, Greece.

Treatment of hepatitis C virus (HCV) infection has been revolutionized with the introduction of pangenotypic, interferon- and ribavirin-free regimens associated with high cure rates and a low side effect profile. Additionally, there is evidence that HCV cure reduces HCV complications, improves patient-reported outcomes and is cost-saving in most western countries in the long term. This is a review of the comprehensive burden of HCV and the value of eliminating HCV infection. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13005
Publisher Site
http://dx.doi.org/10.1111/jvh.13005DOI Listing
November 2018
17 Reads

Characterization of changes in intrahepatic immune cell populations during HCV treatment with sofosbuvir and ribavirin.

J Viral Hepat 2018 Nov 1. Epub 2018 Nov 1.

Division of Infectious Diseases, Medical University of South Carolina, Charleston, South Carolina.

Treatment of chronic hepatitis C virus (HCV) infection with direct-acting antivirals (DAAs) results in a sustained virologic response (SVR) in most patients. While highly efficacious, ~3%-5% of patients do not achieve SVR despite having virus that appears susceptible. It is unclear whether host factors contribute to treatment failures, although innate and adaptive immunity may play a role. Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13034
Publisher Site
http://dx.doi.org/10.1111/jvh.13034DOI Listing
November 2018
1 Read

Non-virological factors are drivers of hepatocellular carcinoma in virosuppressed hepatitis B cirrhosis: Results of ANRS CO12 CirVir cohort.

J Viral Hepat 2018 Oct 31. Epub 2018 Oct 31.

Université Paris 13, Bobigny, France.

Worldwide, hepatocellular carcinoma (HCC) occurs mainly in Asian patients with hepatitis B virus (HBV) infection. This study aimed to decipher the environmental and virological factors associated with HCC occurrence and validate risk scoring systems in a French multicentre prospective cohort of HBV cirrhotic patients. Patients with biopsy-proven Child-Pugh A viral cirrhosis included in the ANRS CO12 CirVir cohort who were HBsAg(+) without hepatitis C coinfection were selected for: (a) interview through a standardized questionnaire reporting coffee consumption and HCC familial history; (b) HBsAg quantification using baseline and sequential 2-year frozen sera; (c) baseline HBV genotype determination; and (d) assessment of risk factors and applicability of HCC risk scores (Kaplan-Meier analysis, Cox models). Read More

View Article

Download full-text PDF

Source
http://doi.wiley.com/10.1111/jvh.13029
Publisher Site
http://dx.doi.org/10.1111/jvh.13029DOI Listing
October 2018
23 Reads

Evaluation and comparison of thirty noninvasive models for diagnosing liver fibrosis in chinese hepatitis B patients.

J Viral Hepat 2019 Feb 28;26(2):297-307. Epub 2018 Nov 28.

Department of Infectious Disease, Center for Liver Disease, Peking University First Hospital, Beijing, China.

The limitations of liver biopsy have led to the development of indirect noninvasive models for liver fibrosis assessment. We aimed to evaluate and compare the performance of 30 noninvasive models to predict fibrosis stage in treatment-naïve and treated chronic hepatitis B (CHB) patients. A total of 576 Chinese treatment-naïve CHB patients and 236 treated CHB patients who had undergone percutaneous liver biopsy were included in the analysis. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13031DOI Listing
February 2019
1 Read

Safety and efficacy of sofosbuvir-based direct-acting antiviral regimens for hepatitis C virus genotype 6 in Southwest China: Real-world experience of a retrospective study.

J Viral Hepat 2018 Oct 31. Epub 2018 Oct 31.

Center of Infectious Diseases, West China Hospital, Sichuan University, Chengdu, China.

Optional treatments for patients with chronic hepatitis C virus (HCV) genotype (GT) 6 infection have not been extensively studied. This study aimed to evaluate the safety and efficacy of sofosbuvir (SOF)-based direct-acting antiviral agents (DAAs) for HCV GT6. We performed a retrospective study at the West China Hospital of Sichuan University in Southwest China from January 2016 to May 2017. Read More

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/jvh.13033DOI Listing
October 2018
1 Read